Table 3 Multiple linear regression for the impact of TOZ on the mean difference in C-reactive protein (CRP) level (CRP baseline-CRP follow−up)
variable | Parameter Estimates | p-value | 95% Confidence Limits | |
|---|---|---|---|---|
TOZ vs. ADM or ETC | 3.83094 | 0.0060* | 1.11550 | 6.54638 |
Age | -0.01850 | 0.6961 | -0.11195 | 0.07495 |
Female vs. male | -2.94758 | 0.1949 | -7.42186 | 1.52670 |
Treatment Duration | 0.21941 | 0.4077 | -0.30290 | 0.74172 |
Disease Duration | 0.00758 | 0.9372 | -0.18225 | 0.19741 |
baseline CRP | 0.72634 | < 0.0001* | 0.60015 | 0.85254 |
baseline ESR | -0.06988 | 0.0022* | -0.11414 | -0.02562 |
number of comorbidities | 0.24384 | 0.1949 | -0.12631 | 0.61400 |
glucocorticoids | -11.42014 | < 0.0001* | -15.14867 | -7.69160 |